Anemia Clinical Trial
Official title:
Assessment of the Effect of Vitamin C on Anemia in Patients With Continuous Ambulatory Peritoneal Dialysi
Among patients with chronic kidney disease (CKD), there is association between anemia and increased chance of mortality mainly because of cardiovascular diseases and stroke, risk of hospitalization, and death prevalence in predialysis patients. Vitamin C plays an important role in iron metabolism and application for red blood cell formation. Infusion of ascorbate supplementation can reduce oxidative stress among hemodialysis patients. This study aimed to assess the effect of vitamin C on patients with continuous ambulatory peritoneal dialysis (CAPD).
World Health Organization (WHO) defines anemia as hemoglobin (Hgb) concentration less than
12.0 g/dL in pre-menopausal women, and lower than 13.0 g/dL in adult males and
post-menopausal women .Diagnosis of anemia is of high significance, as it might be the first
manifestation of a serious illness. Some chronic diseases which also can lead to anemia:
autoimmune disorders, liver cirrhosis, cancer, and chronic renal disease Anemia is
associated with poor prognosis of patients with chronic renal disease, especially those
undergoing long-term hemodialysis. In patients with Glomerular filtration rate (GFR) less
than 25 to 30 mL/min , anemia is observed within 90 percent of patients .
Among patients with chronic kidney disease (CKD), there is association between anemia and
increased mortality secondary to cardiovascular diseases Ascorbic acid level is conflicted
in under dialysis patients with different ranges of low, normal, and even above normal. In
most hemodialysis patients, administration of 150 to 200 mg of vitamin C per day is
recommended to maintain its levels. Ascorbic acid or vitamin C increases the delivery of
iron from ferritin and the reticuloendothelial system and therefore elevates iron use during
heme synthesis.
Vitamin deficiency is one of the cause of increased mortality among hemodialysis patients.
During the dialysis process, vitamins are eliminated through hemodialyzer membranes, thus
affect red blood cell production .Vitamin C deficiency may play an important role in
increased inflammatory status of the dialysis patients . This vitamin has anti-inflammatory
effects due to its electron transfer ability.
Several studies have shown the role of vitamins such as vitamin D and B12 in treatment of
anemia in patients undergoing hemodialysis .The infusion of ascorbate supplementation might
reduce oxidative stress. In addition, vitamin C plays an important role in iron metabolism
and application in red blood cell formation . Permeable membrane is highly associated with a
significant loss of vitamin C, and this vitamin improve oxidative stress in hemodialysis
patients .
We aimed to assess the effect of vitamin C on patients with continuous ambulatory peritoneal
dialysis (CAPD).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
| Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
| Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
| Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
| Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
| Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
| Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
| Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
| Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
| Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
| Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
| Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
| Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 | |
| Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |